Mammography: "Prior research has already suggested this type of association," study leader Hannah Daley of Drexel University ...

The frequency of second primary malignancies (SPMs) arising in cancer survivors following treatment with CAR T-cell therapy was statistically comparable to the frequency of SPMs following other ...

Like Breyanzi, Kymriah, Yescarta, an Tecartus — which achieved revenues of respectively $364m, $508m, $1.5bn and $370m in 2023 — obe-cel targets CD-19, an antigen on the surface of B cells and ...

In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against the other stocks on Jim Cramer’s radar. Jim Cramer often reflects on how he would reform the American ...

Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical company that specializes in innovative drugs across key areas like oncology, rare diseases, neuroscience, and cardio-metabolic ...

2017 saw Novartis deliver to the market one of the most remarkable advances in 21st century medicine, Kymriah, the first ever CAR-T therapy. A ‘living drug’, the therapy could represent a cure ...

Lindy Biosciences has announced an exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG. The deal centres on Lindy’s microglassification technology, which ...

Natco Pharma has submitted to the U.S. Food and Drug Administration an abbreviated new drug application for a generic version of Novartis’ cancer drug Tabrecta (capmatinib hydrochloride).

The trial compared the efficacy of Novartis’ Leqvio as a single agent against ezetimibe and a placebo. Credit: VILTVART/Shutterstock. Novartis has revealed that its Phase III V-MONO clinical trial of ...

Three years after launching Leqvio in the U.S., Novartis is still steadily advancing its blockbuster ambitions for the cholesterol-lowering drug. Early Wednesday, the company touted phase 3 ...

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs. For $20 million ...